You are here

Generic Version of Cipro Approved

TEL AVIV, June 10 (Reuters) - Israeli drug maker Teva Pharmaceutical Industries (NasdaqNM:TEVA - News) has received approval from the U.S. Food and Drug Administration for Ciprofloxacin Tablets in strengths of 250, 500 and 750 mg, it said on Thursday.

The tablets are the generic equivalent of Bayer's (XETRA:BAYG.DE - News) antibiotic Cipro Tablets. Annual sales of the tablets, including those of the brand product and a product sold under licensing agreement with the originator, are about $1 billion.

Teva (Tel Aviv:TEVA.TA - News), the world's biggest generic drug maker, said shipment of the product is expected to begin immediately.

Source: Teva Pharmaceuticals

Recent Headlines

Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
So far in January, the increases average 5%
Fast-acting insulin aspart may simplify mealtime dosing
Simple change in dosage and route may improve a century-old vaccine
Neurodevelopmental deficits detected in Colombian toddlers